(Q81352032)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1 reference

1 reference

Robin C Hilsabeck

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Tarek I Hassanein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Elizabeth A Ziegler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Meghan D Carlson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

William Perry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

Journal of the International Neuropsychological Society

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

16-22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Psychometric monitoring of interferon neurotoxicity

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neuropsychological impairment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Microglial localization of α-interferon receptor in human brain tissues

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Practice effects on commonly used measures of executive function across twelve months

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Reduced quality of life in hepatitis C--is it all in the head?

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Interferon enhances the excitability of cultured neurones

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Prefrontal cortical hypometabolism during low-dose interferon alpha treatment.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Mood and cognitive disorders in cancer patients receiving cytokine therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neurological function during long-term therapy with recombinant interferon alpha

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Psychiatric complications of long-term interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Central nervous system toxicity of interferon

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum laminae terminalis

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Behavioral assessment of patients treated with alpha-interferon.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Cree encephalitis is allelic with Aicardi-Goutiéres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neurological effects of recombinant human interferon

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Persistent neurotoxicity of systemically administered interferon-alpha.

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1017%2FS1355617705050022

7 January 2021

10.1017/S1355617705050022

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15686604%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference